JPMorgan Chase & Co. Grows Stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

JPMorgan Chase & Co. lifted its stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 138.9% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 477,800 shares of the company's stock after purchasing an additional 277,827 shares during the quarter. JPMorgan Chase & Co. owned about 0.66% of Kiniksa Pharmaceuticals worth $9,451,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of KNSA. KLP Kapitalforvaltning AS purchased a new position in shares of Kiniksa Pharmaceuticals in the fourth quarter worth about $158,000. China Universal Asset Management Co. Ltd. increased its position in shares of Kiniksa Pharmaceuticals by 12.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,814 shares of the company's stock worth $174,000 after purchasing an additional 1,004 shares in the last quarter. Teacher Retirement System of Texas increased its stake in Kiniksa Pharmaceuticals by 7.1% in the fourth quarter. Teacher Retirement System of Texas now owns 10,862 shares of the company's stock valued at $215,000 after purchasing an additional 719 shares during the period. Y Intercept Hong Kong Ltd purchased a new stake in shares of Kiniksa Pharmaceuticals during the fourth quarter worth approximately $258,000. Finally, New York State Common Retirement Fund lifted its holdings in shares of Kiniksa Pharmaceuticals by 12.4% in the 4th quarter. New York State Common Retirement Fund now owns 15,248 shares of the company's stock valued at $302,000 after buying an additional 1,680 shares during the period. Hedge funds and other institutional investors own 53.95% of the company's stock.

Kiniksa Pharmaceuticals Trading Down 1.6 %

Shares of NASDAQ KNSA traded down $0.32 during mid-day trading on Friday, reaching $20.21. 529,238 shares of the company's stock were exchanged, compared to its average volume of 463,295. Kiniksa Pharmaceuticals, Ltd. has a twelve month low of $16.87 and a twelve month high of $28.15. The firm has a market capitalization of $1.47 billion, a price-to-earnings ratio of -144.35 and a beta of 0.31. The business has a fifty day simple moving average of $21.05 and a 200 day simple moving average of $21.47.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last announced its earnings results on Tuesday, February 25th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.06). The company had revenue of $122.50 million for the quarter, compared to the consensus estimate of $123.42 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The business's quarterly revenue was up 46.9% on a year-over-year basis. During the same period in the previous year, the firm posted $0.35 EPS. Equities research analysts predict that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current fiscal year.

Analysts Set New Price Targets

KNSA has been the subject of a number of analyst reports. Citigroup began coverage on shares of Kiniksa Pharmaceuticals in a research report on Thursday, March 13th. They issued a "buy" rating and a $40.00 price objective for the company. Wedbush restated an "outperform" rating and issued a $34.00 price target on shares of Kiniksa Pharmaceuticals in a research report on Wednesday. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Kiniksa Pharmaceuticals has a consensus rating of "Buy" and a consensus price target of $37.17.

Insider Buying and Selling

In other news, COO Eben Tessari sold 14,000 shares of Kiniksa Pharmaceuticals stock in a transaction on Monday, February 10th. The stock was sold at an average price of $19.57, for a total transaction of $273,980.00. Following the sale, the chief operating officer now directly owns 81,975 shares in the company, valued at $1,604,250.75. The trade was a 14.59 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Mark Ragosa sold 36,372 shares of Kiniksa Pharmaceuticals stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $22.25, for a total transaction of $809,277.00. Following the completion of the transaction, the chief financial officer now owns 22,958 shares of the company's stock, valued at $510,815.50. The trade was a 61.30 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 91,766 shares of company stock valued at $2,002,135 in the last three months. Insiders own 54.57% of the company's stock.

Kiniksa Pharmaceuticals Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.